{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:27:41Z","timestamp":1786123661028,"version":"build-2736575974"},"reference-count":13,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Ophthalmol"],"abstract":"<jats:p>Introduction: Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists, such as tirzepatide, have significantly advanced the management of type 2 diabetes mellitus and obesity. However, emerging safety signals have raised concerns regarding rare ocular adverse events. Case Presentation: We report a case of an obese patient undergoing treatment with tirzepatide who presented with progressive, painless visual loss in the left eye 2 weeks after symptom onset. Four weeks prior to presentation, she had initiated tirzepatide therapy for weight reduction at a dose of 15 mg once weekly without standard dose titration. Best-corrected visual acuity was 20\/20 in the right eye and counting fingers at 1 meter in the left eye. Fundus examination revealed hyperemic optic disc oedema with peripapillary flame-shaped haemorrhages. Automated perimetry demonstrated a central scotoma. MRI of the brain and orbits excluded intracranial pathology and showed no optic nerve enhancement. Intravenous methylprednisolone was administered, after which visual acuity improved to 20\/40. Conclusion: Regulatory and pharmacovigilance data suggest that NAION may represent a very rare adverse event associated with GLP-1 receptor agonists, with observational studies indicating a possible association for tirzepatide, although absolute risk appears low and causality remains unproven. While the relationship between dual GIP\/GLP-1 receptor agonists and NAION remains controversial, clinicians \u2013 particularly ophthalmologists \u2013 should remain vigilant and consider this potential risk when evaluating the benefit-risk profile for individual patients.<\/jats:p>","DOI":"10.1159\/000552569","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:01:19Z","timestamp":1781798479000},"page":"806-813","source":"Crossref","is-referenced-by-count":0,"title":["Acute Unilateral NAION following Tirzepatide Therapy: A Case Report"],"prefix":"10.1159","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4740-2587","authenticated-orcid":false,"given":"Jela","family":"Val\u00e1\u0161kov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmytro","family":"Bondarchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kadlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ter\u00e9zia","family":"Ka\u0161\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Plesnikov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6058"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26327"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0805-8"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3451-6"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.03.032"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c190021"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1990.39"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0469"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32831eef82"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2012.04.004"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160112031"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1878-5085-4-14"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X20913609"}],"container-title":["Case Reports in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:00:51Z","timestamp":1786118451000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000552569","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32725848","asserted-by":"subject"}]},"ISSN":["1663-2699"],"issn-type":[{"value":"1663-2699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}